"Diabetic foot ulcers continue to be a major health challenge and with over 8% of the Singapore population being diabetic, any wound that remains unhealed after 4 weeks is a cause for concern, as it is associated with worse outcomes, including amputations."

U.S. Company, Advanced BioHealing, Inc., based in La Jolla, California, is the manufacturer of Dermagraft®, a cryopreserved human fibroblast-derived dermal substitute currently indicated for use in the treatment of full-thickness diabetic foot ulcers.

It is composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold.  Dermagraft® is unique as it promotes re-epithelialization - assisting in the restoration of the dermal bed, allowing wounds to heal.  It also has a longer shelf life than its closest competitor.

Dermagraft® has been demonstrated in clinical trials to improve healing of diabetic foot ulcers in four elements to the chronic wound repair process:

1. Supply living, nonsenescent fibroblasts that are capable of colonizing the wound bed and persisting.
2. Provide fibroblast-derived cytokines, particularly angiogenic growth factors.
3. Function as a permissive, performed, normal human matrix for keratinocyte migration.
4. Release cytokines capable of reducing chronic wound inflammation.

For more information, please visit: http://www.AdvancedBioHealing.com

The ideal distributor should be able to handle full marketing, sales and distribution and sell to vascular surgeons, podiatrists, diabetic centers, etc.

If you are keen to be a distributor and interested to learn more about this product, please complete and submit the form below.  Please respond by Friday, November 21, 2008.

Questions?

Please contact Luanne Theseira at 6476-9416, email at Luanne.Theseira@N0SPAM.mail.doc.gov or Sherry Ng at 6476-9349, email at Sherry.Ng@N0SPAM.mail.doc.gov

RESPONSE FORM